- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00538681
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
2020. október 9. frissítette: Eli Lilly and Company
Randomized, Double-Blind, Placebo Controlled, Phase 2 Study of Pemetrexed and Cisplatin Plus Enzastaurin Versus Pemetrexed and Cisplatin Plus Placebo in Chemonaive Patients With Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy. The study will be conducted in 2 parts:
- Part 1 is intended to evaluate safety of pemetrexed + cisplatin + enzastaurin combination chemotherapy
- Part 2 whose main objective is to compare the efficacy of pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo. Participants to be included in Part 2 are those with Nonsquamous Non-Small Cell Lung Cancer (NSCLC).
A tanulmány áttekintése
Állapot
Megszűnt
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
35
Fázis
- 2. fázis
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
-
Leuven, Belgium, 3000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Otwock, Lengyelország, 05-400
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Poznan, Lengyelország, 60-569
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Gauting, Németország, 82131
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
GroBhansdorf, Németország, D-22927
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hamburg, Németország, D 21075
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Heidelberg, Németország, 69126
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Bergamo, Olaszország, 24128
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Catania, Olaszország, 95100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Padova, Olaszország, 35128
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Trento, Olaszország, 38100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Bucharest, Románia, 022328
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
18 év és régebbi (Felnőtt, Idősebb felnőtt)
Egészséges önkénteseket fogad
Nem
Tanulmányozható nemek
Összes
Leírás
Inclusion Criteria:
- diagnosis of advanced NSCLC not amenable to curative treatment. Participants enrolling in Part 2 of the study must have the above stated diagnosis of NSCLC that is also of nonsquamous histology.
- no prior systemic therapies [chemotherapy, et cetera (etc.)] or pleurodesis with chemotherapy for this disease
- prior radiotherapy is allowed but must be completed at least 2 weeks before study enrollment and participant must be recovered from the acute toxic effects
- have a good performance status
- participant must sign an informed consent document
Exclusion Criteria:
- participant had myocardial infarction occurring less than 6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications
- participant is unable to swallow tablets
- participant is taking a certain medicine to control seizure activity, called "enzyme inducing antiepileptic drugs" and is not able to stop taking the medicine prior to enrolling in the study
- participant is unable to interrupt aspirin and/or other anti-inflammatory agents
- participant is unwilling or unable to take vitamin supplementation (folic acid and vitamin B12) or medications to prevent side effects
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Hármas
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Enzastaurin + Pemetrexed + Cisplatin
|
1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
Más nevek:
500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
Más nevek:
75 mg/m², IV, every 21 days, for each 21-day cycle
|
Placebo Comparator: Placebo + Pemetrexed + Cisplatin
|
500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
Más nevek:
75 mg/m², IV, every 21 days, for each 21-day cycle
po, QD
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Part 1: Evaluate Safety [Toxicity, Serious Adverse Events (SAEs) and Reasons for Participant's Discontinuation]
Időkeret: Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow up
|
Presented are data that evaluates safety based on toxicity using Common Terminology Criteria for Adverse Events (CTCAE v3.0), SAEs, and discontinuations due to SAEs or other non-serious adverse events (AE's) of study participants.
A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Event module.
|
Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow up
|
Part 2: Compare Progression-Free Survival (PFS) Between the 2 Treatment Arms Through the Assessment of Tumor Response
Időkeret: Baseline to measured PD up to 5 months
|
PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause.
For participants not known to have died as of the data cut-off date and who did not have objective progressive disease (PD), PFS was censored at the date of the last objective progression-free assessment.
For participants who received subsequent anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression or death, PFS was censored at the date of last objective progression-free assessment prior to the initiation of post discontinuation anticancer therapy.
PFS was calculated and analyzed based on an alternative definition of censoring; for each participant who is not known to have died or who have had objective disease progression as of the data cut-off date, PFS was censored at the date of last prior contact.
Zero participants were analyzed in this outcome as study was terminated early.
|
Baseline to measured PD up to 5 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Part 2: To Evaluate the Safety and Toxicity Profile of Study Treatments
Időkeret: Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow-up
|
The safety and toxicity profile for Part 2 was defined as serious adverse events (SAEs) and other non-serious adverse events (AEs).
A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Event module.
|
Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow-up
|
Part 2: Number of Participants With a Complete Response (CR) or Partial Response (PR) (Response Rate)
Időkeret: Baseline to measured progressive disease (PD) up to 5 months
|
Response rate was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria.
Complete Response (CR) was defined as the disappearance of all target lesions.
Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter (LD) of target lesions.
Best response was confirmed by a second assessment in ≥28 days.
Response rate was defined as the number of participants with best response of CR or PR divided by the total number of treated participants.
Zero participants were analyzed in this outcome as study was terminated early.
|
Baseline to measured progressive disease (PD) up to 5 months
|
Part 2: Overall Survival (OS)
Időkeret: Baseline to date of death from any cause up to 5 months
|
OS time was defined as the time from the date of study enrollment to the date of death from any cause.
For participants not known to have died as of the data cut-off date, OS was censored at the last contact date (last contact for participants in post discontinuation was equal to the last known alive date in mortality status).
Zero participants were analyzed in this outcome as study was terminated early.
|
Baseline to date of death from any cause up to 5 months
|
Part 2: Duration of Disease Control (DDC) and Response
Időkeret: Baseline to measured PD up to 5 months
|
DDC and response defined as time from complete response (CR), partial response (PR) or stable disease (SD) to first date of objectively determined progressive disease (PD) or death from any cause using RECIST (v1.0) criteria.
CR defined as disappearance of all target lesions.
PR defined as having ≥30% decrease in sum of longest diameter (LD) of target lesions.
PD defined as having ≥20% increase in the sum of the LD of target lesions.
SD defined as small changes not meeting above criteria.
Participants not known to have died as of data cut-off date, had no objective PD or were lost to follow-up, DCC was censored at date of last objective progression-free assessment (OPFA).
Participants who received subsequent anticancer therapy (after discontinuation from study treatment) prior to objective PD or death were censored at date of last OPFA prior to initiation of post discontinuation anticancer therapy.
Zero participants were analyzed in this outcome as study was terminated early.
|
Baseline to measured PD up to 5 months
|
Part 2: Time to Worsening of Symptoms (TWS)
Időkeret: Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow-up
|
TWS was measured from the date of study enrollment to the first date of a worsening in any of the 6 Lung Cancer Symptom Scale (LCSS) symptoms (appetite, cough, fatigue, shortness of breath, hemoptysis and pain).
Participants marked each symptom on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (as good as it can be/none) to 100 mm (as bad/much as it could be).
TWS was also measured individually for each of the 6 symptoms independently and were also measured from the date of enrollment to the first date of worsening in pain.
For both measurements, worsening was defined as a 15-mm increase from baseline in the participant-reported score for any symptom.
Participants who are not known to have had a worsening TWS were censored at the date of the participant's last LCSS assessment.
Zero participants were analyzed in this outcome as study was terminated early.
|
Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and 30-day follow-up
|
Part 2: To Assess Biomarkers of the Disease State and Their Correlation to Clinical Outcome
Időkeret: Baseline, Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and end of study up to 5 months
|
Presented are data that evaluates of biomarkers relevant to the study drug and the disease state of the participant's clinical outcome.
Zero participants were analyzed in this outcome as study was terminated early.
|
Baseline, Cycle 1 (28-day cycle), Cycles 2, 3, 4, 5, and 6 (21-day cycles) and end of study up to 5 months
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Nyomozók
- Tanulmányi igazgató: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UCT/GMT - 5 hours, EST), Eli Lilly and Company
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete
2007. szeptember 1.
Elsődleges befejezés (Tényleges)
2008. november 1.
A tanulmány befejezése (Tényleges)
2008. november 1.
Tanulmányi regisztráció dátumai
Először benyújtva
2007. október 1.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2007. október 1.
Első közzététel (Becslés)
2007. október 3.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2020. november 5.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2020. október 9.
Utolsó ellenőrzés
2020. október 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 10722
- H6Q-MC-S021 (Egyéb azonosító: Eli Lilly and Company)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Tüdőrák
-
Seoul National University HospitalBefejezveLung ComplianceKoreai Köztársaság
-
Alexandria UniversityMég nincs toborzásLégzőkészülék tüdő | Echokardiográfia | Lung Recruitment | Mellkasi ultrahang | Nagyfrekvenciás szellőztetésEgyiptom
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktív, nem toborzóÁttétes tüdő nem kissejtes karcinóma | Tűzálló tüdő nem kissejtes karcinóma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | IVA stádiumú tüdőrák AJCC v8 | IVB stádiumú tüdőrák AJCC v8Egyesült Államok
-
Novartis PharmaceuticalsBefejezveNeuroendokrin daganatok | Advanced NET of GI Origin | Lung Origin fejlett NETEgyesült Államok, Colombia, Olaszország, Tajvan, Egyesült Királyság, Belgium, Csehország, Németország, Japán, Szaud-Arábia, Kanada, Hollandia, Spanyolország, Koreai Köztársaság, Libanon, Ausztria, Kína, Görögország, Dél-Afrika, Thaiföl... és több
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)ToborzásAnatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Korai stádiumú emlőkarcinóma | Anatómiai Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Egyesült Államok
-
Tanta UniversityBefejezveGerincferdülés; Serdülőkor | Posztoperatív atelektázia | Lung RecruitmentEgyiptom
-
Assiut UniversityMég nincs toborzásTüdőrák | Tüdősérülés | Bleb Lung
-
CSA Medical, Inc.VisszavontTüdőbetegségek, obstruktív | Légúti elzáródás | Lung Disease Airways | Légút; Elzáródás, Emfizémával
-
University of LorraineBefejezveGyermek, csak | Spontán pneumothorax | Idiopátiás pneumothorax | Bleb LungFranciaország
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok